Short Interest in Exicure, Inc. (NASDAQ:XCUR) Rises By 7,428.3%
by Tristan Rich · The Markets DailyExicure, Inc. (NASDAQ:XCUR – Get Free Report) was the target of a large increase in short interest in July. As of July 15th, there was short interest totaling 506,729 shares, an increase of 7,428.3% from the June 30th total of 6,731 shares. Based on an average daily trading volume, of 2,149,123 shares, the short-interest ratio is presently 0.2 days. Approximately 16.8% of the shares of the stock are short sold.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings cut shares of Exicure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 11th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.
View Our Latest Report on Exicure
Exicure Stock Up 2.9%
XCUR traded up $0.05 on Friday, reaching $1.76. 52,895 shares of the company traded hands, compared to its average volume of 193,801. Exicure has a one year low of $1.43 and a one year high of $9.48. The firm has a fifty day simple moving average of $2.40 and a two-hundred day simple moving average of $3.62. The company has a market cap of $11.21 million, a P/E ratio of -1.14 and a beta of 3.61.
Exicure (NASDAQ:XCUR – Get Free Report) last posted its quarterly earnings data on Friday, May 29th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($18.60) by $18.31.
Exicure Company Profile
Exicure is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.
The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.